News | August 12, 2021
Mangalam Drugs signs tech transfer agreement with Nigerian pharma company
Anti-malaria API facility will be operational in 15-18 months
Anti-malaria API facility will be operational in 15-18 months
The collaboration will support Canada with direct access to rapid pandemic response capabilities
Filing for WHO Emergency Use Authorisation this month
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
CDSCO to fast-track trials and approval for COVID19 vaccine
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The group now has 320 approvals and has so far filed over 400 ANDAs
The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector
Subscribe To Our Newsletter & Stay Updated
